Browsing tag:

MS


Known as the brand name anti-epileptic drug Dilantin, Phenytoin has recently piqued the interests of Multiple Sclerosis research and development teams. Study results shared from the National Hospital for Neurology and Neurosurgery in London have been hopeful for patients with MS who were treated with Phenytoin, in response to their cases of acute optic neuritis.[…]

Read More

Known as the brand name Campath, which is marketed by Genzyme, Alemtuzumab is a proven therapy for leukemias, lymphomas and recently, multiple sclerosis. As a monoclonal antibody Alemtuzumab effectively binds to the CD52 protein which occurs on cancerous B and T cell lymphocytes. After attaching to the protein on the cells Alemtuzumab elicits other immune[…]

Read More

Alemtuzumab, also known as the brand name MS drug Lemtrada, has recently gained a long awaited FDA approval. Genzyme spent over a decade developing this long-acting agent designed to effectively treat patients with relapsing Multiple Sclerosis. The unique method of dispensing Alemtuzumab is a significant plus for patients who do not tolerate current medication regimens[…]

Read More

Glatiramer, CAS# 28704-27-0, and Glatiramer Acetate, CAS# 147245-92-9, are also known as Copaxone. In the spotlight recently, Copaxone’s patent is due to expire on May 24, 2014. The flurry of interest regarding Copaxone follows the devastating diagnosis of Multiple Sclerosis for beloved reality star Jack Osbourne. In mid June of 2012 reports surfaced about Jack’s[…]

Read More

This website uses cookies. By using our site, you agree to our terms of service